The Board of Trustees of the Josep Carreras Leukaemia Research Institute has approved the appointment of Dr Ari Melnick as the new Director of the centre. Dr Melnick will take on the leadership of the Institute, which focuses on leukaemia and other haematological malignancies research.
Dr Ari Melnick has been appointed the new Director of the Josep Carreras Leukaemia Research Institute by the Board of Trustees. Founded in 2010 by the Government of Catalonia and the Josep Carreras Leukaemia Foundation and based in Badalona, the Josep Carreras Institute specialises in biomedical research and precision medicine in the field of leukaemia and other hematologic malignancies.
Dr Ari Melnick brings extensive experience in haematological research to the Josep Carreras Institute. He graduated in Medicine from the University of Buenos Aires in 1990 and has worked at prestigious institutions such as the Mount Sinai School of Medicine and the Weill Cornell Cancer Center (New York, USA), where he has led the “Hematologic Malignancies Program” and been “Gebroe Family” Professor since 2013. Internationally recognised in the field of haematological diseases and cancer epigenetics, Dr Melnick was among the first to develop rationally designed transcription factor inhibitors and conduct large-scale epigenomic studies in humans. His research demonstrated that aberrant epigenetic programming is a hallmark of cancer, and that epigenetic diversity is a fundamental determinant of tumour fitness and unfavourable clinical outcomes. He has authored more than 360 manuscripts, and therapeutic approaches he developed and identified have been approved by the FDA or moved to phase III clinical trials. For this he has been awarded the American Society of Hematology Ernest Beutler Prize in Translational Research. Dr Melnick serves on the Board of Directors of the Leukemia and Lymphoma Society and the Lymphoma Research Foundation.
